Dyne Therapeutics (NASDAQ:DYN) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Dyne Therapeutics (NASDAQ:DYN) issued its earnings results on Monday. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02), FiscalAI reports.

Dyne Therapeutics Stock Down 3.7%

Shares of Dyne Therapeutics stock traded down $0.58 during trading on Monday, hitting $15.04. 621,577 shares of the stock traded hands, compared to its average volume of 1,984,582. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14. The stock’s fifty day simple moving average is $17.57 and its 200 day simple moving average is $17.01. Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $25.00. The firm has a market cap of $2.15 billion, a P/E ratio of -4.13 and a beta of 1.34.

Hedge Funds Weigh In On Dyne Therapeutics

Large investors have recently added to or reduced their stakes in the company. Creative Planning lifted its position in Dyne Therapeutics by 6.8% during the third quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after acquiring an additional 986 shares during the last quarter. Caxton Associates LLP increased its stake in Dyne Therapeutics by 10.9% during the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after purchasing an additional 1,627 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its stake in shares of Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after acquiring an additional 2,886 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in Dyne Therapeutics by 12.1% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 33,547 shares of the company’s stock valued at $656,000 after purchasing an additional 3,628 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on DYN shares. TD Cowen reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, December 8th. Evercore lowered their price target on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Wednesday, January 21st. JPMorgan Chase & Co. lowered their price objective on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. Finally, Robert W. Baird set a $30.00 target price on Dyne Therapeutics in a research report on Monday, December 8th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.81.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.